Objectives: To describe an outpatient treatment model for treating non-Hodgkin's lymphoma with radioimmunotherapy.
Data Sources: Experiences of The Hoag Cancer Canter (Newport Beach, CA) in developing an outpatient treatment model.
Conclusions: The Hoag Cancer Center has put an outpatient radioimmunotherapy treatment model into place. Goals include providing coordinated, collaborative care, safe delivery of radioimmunotherapy in an outpatient setting, and establishing an education program for the medical team, patient, and patient's family.
Implications For Nursing Practice: In providing outpatient treatment for non-Hodgkin's lymphoma, nurses will have many functions, including educating patients and family, coordinating treatment schedules, adhering to radiation safety guidelines, and reviewing post-therapy and long-term side effects that might occur at home.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/sonu.2002.31562 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A phase I trial of CC-486, lenalidomide, obinutuzumab in relapsed/refractory indolent non-Hodgkin lymphoma.
Leuk Lymphoma
December 2024
Department of Internal Medicine, Division of Malignant Hematology/Cellular Therapy and Transplantation, University of California Davis School of Medicine, Sacramento, CA, USA.
Incidental finding of intravascular large B cell lymphoma in a multinodular goiter.
Malays J Pathol
December 2024
Universiti Kebangsaan Malaysia, Faculty of Medicine, Department of Pathology, Kuala Lumpur, Malaysia.
No abstract available.
View Article and Find Full Text PDFRevealing the heterogeneity of treatment resistance in less-defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy.
Clin Transl Med
January 2025
Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Precision medicine in less-defined subtype diffuse large B-cell lymphoma (DLBCL) remains a challenge due to the heterogeneous nature of the disease. Programmed cell death (PCD) pathways are crucial in the advancement of lymphoma and serve as significant prognostic markers for individuals afflicted with lymphoid cancers. To identify robust prognostic biomarkers that can guide personalized management for less-defined subtype DLBCL patients, we integrated multi-omics data derived from 339 standard R-CHOP-treated patients diagnosed with less-defined subtype DLBCL from three independent cohorts.
View Article and Find Full Text PDFPrognostic value of interim PET/CT in GCB and non-GCB DLBCL: comparison of the Deauville five-point scale and the ΔSUVmax method.
BMC Cancer
December 2024
Department of Nuclear Medicine, School of Medicine, Shanghai General Hospital, Shanghai JiaoTong University, Shanghai, 200080, China.
Background: This study aimed to identify the prognostic value of interim F-FDG PET/CT (I-PET) for germinal center B-cell-like (GCB) and non-GCB diffuse large B-cell lymphoma (DLBCL), respectively.
Methods: Baseline F-FDG PET/CT (B-PET) and I-PET scans were performed in 112 patients with DLBCL. The prognostic value of I-PET using the Deauville five-point scale (D-5PS) criteria or percentage decrease in SUVmax (∆SUVmax) for GCB and non-GCB DLBCL were evaluated.
A case of uveoscleral mucosa-associated lymphoid tissue lymphoma with secondary angle-closure glaucoma.
BMC Ophthalmol
December 2024
Department of Ophthalmology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, N-15, W-7, Kita-ku, Sapporo, 060-8638, Japan.
Background/aim: Mucosa-associated lymphoid tissue (MALT) lymphomas occur in not only the ocular adnexa, but rarely in the sclera or uvea. Histopathological confirmation contributes to a better understanding of the pathogenesis and treatment. We report a case of uveoscleral MALT lymphoma with angle-closure glaucoma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!